Analysts Boost Harrow Price Targets Amid Strong Growth Prospects and Pipeline Optimism

AN

AnalystConsensusTarget

AnalystConsensusTarget

Not Invested

Based on Analyst Price Targets

Published

05 May 25

Updated

05 Dec 25

Views

246

n/a

n/a

AnalystConsensusTarget's Fair Value

n/a

1Y

30.3%

7D

-5.5%

Loading

1Y

30.3%

7D

-5.5%

You can edit this narrative until Dec 6 1:10 PM. Then, changes will post as Updates.

Author's Valuation

US$70.6335.3% undervalued

AnalystConsensusTarget Fair Value

Shared on 05 Dec 25

HROW: Expanding Ophthalmic Portfolio Will Drive Long-Term Revenue Mix Diversification

Analysts have raised their blended price targets for Harrow into a higher range, highlighted by recent increases to $66, $70, $74, and $94 per share. They cite a stronger long-term revenue and margin outlook supported by ophthalmic biosimilars, Vevye ramp expectations, and a more visible commercial roadmap.

Shared on 21 Nov 25

Fair value Increased 3.59%

HROW: Expanding Ophthalmic Pipeline Will Drive Revenue Upside Beyond 2026

Analysts have raised their price target for Harrow from $68.18 to $70.63. They cite sustained confidence in the company's revenue growth potential and the strength of its commercial roadmap, despite slight adjustments in growth projections and profit margins.

Shared on 05 Nov 25

HROW: Expanding Ophthalmic Pipeline Will Drive Strong Revenue Momentum Through 2027

Analysts have raised their price targets for Harrow. The most recent consensus lifts expectations by up to $4 per share, citing confidence in the company's expanding pipeline and commercial strategy to deliver sustainable revenue and margin growth.

Shared on 22 Oct 25

Analysts have raised their average price target for Harrow, citing increased confidence in the company's commercial execution and long-term revenue growth potential. Recent updates reflect new targets up to $74, compared to previous levels between $42 and $70.

Shared on 08 Oct 25

Fair value Increased 10%

Harrow's analyst price target has increased from $61.98 to $68.18. Analysts point to a stronger revenue growth outlook and heightened optimism regarding the company's commercial execution and product pipeline.

Shared on 24 Sep 25

Fair value Increased 3.12%

Analysts have raised Harrow's price target to $61.98, reflecting optimism about upcoming biosimilar launches, a strengthening market position in eye care, and expectations for upside to current revenue guidance. Analyst Commentary Introduction of ophthalmic biosimilars Byooviz and Opuviz expected to materially contribute to revenue starting in 2026.

AnalystConsensusTarget Fair Value

US$70.63

35.3% undervalued

Future estimation in

Growth p.a.

Growth p.a.

%

Decrease

Increase

Current revenue growth rate

30.14%

Pharma revenue growth rate

0.63%

Risk Level (Discount Rate)

Our default considers factors like the company's size, volatility, profitablity and country of operation.

%

0

Decrease

Increase

Current discount rate

6.96%

Calculation

US$179.94m

Earnings '28

x

19.69x

PE Ratio '28

=

US$3.54b

Market Cap '28

US$3.54b

Market Cap '28

/

41.52m

No. shares '28

=

US$85.33

Share Price '28

US$85.33 Share Price '28

Discounted to 2025 @ 6.96% p.a.

=

US$69.74

Fair Value '25